10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 4 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Doxifluridine Doxifluridine (5'-DFUR, AMC 0101) is an oral prodrug that is converted to the cytotoxic agent 5-fluorouracil (5-FU).
In vitro
Doxifluridine suppresses tube formation of HUVEC and vascular endothelial growth factor production by FU-MMT-1 cells. Doxifluridine is converted to 5-FU and subsequently to FdUMP, and the results suggest that Doxifluridine exerts its cytotoxic effects through inhibition of TS and incorporation into RNA. Doxifluridine is a fluoropyrimidine derivative that is activated preferentially in malignant cells by thymidine phosphorylase to form 5-fluorouracil (5-FU). Doxifluridine is developed to improve the therapeutic index of 5-FU and to reduce toxicity, including the immunosuppressive, myelosuppressive, and cardiotoxic effects of 5-FU and other fluorinated pyrimidines.
In vivo
Metronomic Doxifluridine alone significantly suppresses tumor growth compared with the untreated (control) group, while metronomic Doxifluridine in combination with TNP-470 significantly inhibits tumor growth compared with each treatment alone in in FU-MMT-1 xenografts. Doxifluridine in combination with TNP-470 also leads to a significant reduction of intratumoral vascularity. Doxifluridine significantly inhibits the growth of KPL-4 tumors, reduces the tissue levels of IL-6, and alleviates body weight loss in nude mice bearing KPL-4 tumors. Doxifluridine results in a significant reduction in the activity of phenytoin p-hydroxylation in rats. Doxifluridine decreases the elimination rate constant and the total clearance in rats.
Cell Data
cell lines：OSA cells
Concentrations：
Incubation Time：
Powder Purity:≥99%
| ALogP | -1.7 |
|---|
| 異性体SMILES | C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O |
|---|---|
| RTECS | YU7526000 |
| 分子量 | 246.19 |
| Reaxy-Rn | 15437367 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=15437367&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| 溶解度 | Solubility (25°C) In vitro Ethanol: mg/mL |
|---|---|
| 比旋光度［α］ | 20° (C=1,H2O) |
| 融点（°C） | 189 °C |
| 1. Jiao Sha, Ruke Zhang, Yuanyuan Zun, Rui Zhao, Yameng Wan, Haixia He, Renren Sun, Gaoliang Jiang, Yu Li, Tao Li, Baozeng Ren. (2020) Equilibrium solubility, thermodynamic properties and Hansen solubility parameter of doxifluridine in (±)-2-ethyl-1-hexanol + (methanol, ethanol and acetone) at various temperatures. JOURNAL OF MOLECULAR LIQUIDS, [PMID:] [10.1016/j.molliq.2020.114130] |
| 2. Jiao Sha, Teng Ma, Rui Zhao, Pengshuai Zhang, Renren Sun, Gaoliang Jiang, Yameng Wan, Haixia He, Xinding Yao, Yu Li, Tao Li, Baozeng Ren. (2020) The dissolution behaviour and apparent thermodynamic analysis of doxifluridine in twelve pure solvents at various temperatures. JOURNAL OF CHEMICAL THERMODYNAMICS, [PMID:] [10.1016/j.jct.2020.106073] |
| 3. Wang Xue-jie, You Jin-zong. (2015) Study on the thermal decomposition of capecitabine. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 123 (3): (2485-2497). [PMID:] [10.1007/s10973-015-4857-9] |
| 4. Xinqi Qiu, Minhui Zhang, Yan Liu, Mingao Li, Quanzhou Wu, Jianfeng He. (2024) Novel water-compatible surface molecularly imprinted polymer microspheres based on boronate affinity and hydrophilic coating for efficient enrichment and separation of capecitabine from urine samples. MICROCHEMICAL JOURNAL, [PMID:] [10.1016/j.microc.2024.111289] |
